Outcomes by baseline tumor burden using the 6-and-12 score in EMERALD-1: A phase 3 study of durvalumab (D) ± bevacizumab (B) with transarterial chemoembolization (TACE) in embolization-eligible unresectable hepatocellular carcinoma (uHCC).
Authors
Muhammad Shaalan Beg (ORCID: https://orcid.org/0000-0002-3754-6627)
В. В. Бредер (ORCID: https://orcid.org/0000-0002-6244-4294)
Outcomes by baseline tumor burden using the 6-and-12 score in EMERALD-1: A phase 3 study of durvalumab (D) ± bevacizumab (B) with transarterial chemoembolization (TACE) in embolization-eligible unresectable hepatocellular carcinoma (uHCC).
Muhammad Shaalan Beg, В. В. Бредер, Zhenggang Ren, Masatoshi Kudo et al.
Journal
Journal of Clinical Oncology
Topics
Hepatocellular Carcinoma Treatment and Prognosis
article
Outcomes by baseline tumor burden using the 6-and-12 score in EMERALD-1: A phase 3 study of durvalumab (D) ± bevacizumab (B) with transarterial chemoembolization (TACE) in embolization-eligible unresectable hepatocellular carcinoma (uHCC).
Muhammad Shaalan Beg, В. В. Бредер, Zhenggang Ren, Masatoshi Kudo, Rebecca Griffin, Joseph P. Erinjeri, Jeong Heo, Sajid Ali, Stephen L. Chan, Kavitha Balaji, Thomas Decaens, Mohamed Bouattour, Bruno Sangro, Chang-Fang Chiu
article en
Abstract
No abstract available for this paper.
Publication Tag
Journal of Clinical OncologyVol. 43(16_suppl)
Institutions
AstraZeneca (United Kingdom) (GB), Memorial Sloan Kettering Cancer Center (US), Inserm (FR), Chinese University of Hong Kong (HK), China Medical University (TW), Fudan University (CN), Hôpital Beaujon (FR), Centre Hospitalier Universitaire de Grenoble (FR), Assistance Publique – Hôpitaux de Paris (FR), Prince of Wales Hospital (CN), Centro de Investigación Biomédica en Red (ES), Pusan National University Hospital (KR), China Medical University Hospital (TW), Zhongshan Hospital (CN), Clinica Universidad de Navarra (ES), National Medical Research Center of Cardiology (RU), AstraZeneca (United States) (US), Southwestern Medical Center (US), The University of Texas Southwestern Medical Center (US), Université Grenoble Alpes (FR), Kindai University (JP)